S2 Fusion Peptide Antigen for Escape-Resistant SARS-CoV-2 Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines and detection methods for SARS-CoV-2 are not broad-spectrum and struggle with SARS-CoV-2 escape mutants, lacking effective immunological strategies and rapid detection for anti-S2 antibodies.
Innovation Solution
Development of a broad-spectrum peptide antigen and fusion protein with a specific amino acid sequence (SEQ ID NO: 1) that remains consistent across SARS-CoV-2 strains, including mutants, and a method for producing a neutralizing antibody through PCR amplification and recombinant cloning, enabling rapid and reliable detection and vaccine development.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RBD-based vaccine strategy is used, then immunological advantage is achieved, but effectiveness deteriorates due to escape mutants
Solution Approach 1:
The patent segments the S protein into functional domains (S1-RBD and S2-FP) and focuses on the conserved S2 subunit as the vaccine target, separating the approach from RBD-based strategies. This segmentation allows targeting of conserved regions that escape mutants cannot easily alter.
Solution Approach 2:
The patent changes the target parameter from RBD to S2 subunit, specifically targeting the fusion peptide region which is highly conserved across coronavirus strains. This parameter change enables broad-spectrum coverage including SARS-CoV-2 and other coronaviruses.
2Adaptability or versatility
If broad-spectrum vaccine is developed, then coverage across strains is improved, but detection method availability deteriorates
Solution Approach 1:
The patent creates a universal detection system where the same S2-based antigen can be used for both vaccine development and antibody detection. The conserved S2 peptide serves dual purposes: as vaccine immunogen and as detection antigen in ELISA kits, eliminating the need for separate detection methods.
3Speed
If rapid detection method is developed, then detection speed is improved, but specificity across mutants deteriorates
Solution Approach 1:
The patent focuses on a specific local region (S2 fusion peptide) that is highly conserved across all coronavirus strains. By targeting this specific conserved region, the detection method achieves both rapid results and high specificity, as the conserved sequence remains recognizable despite mutations in other regions.
Data Source
AI summary
The present disclosure provides a broad-spectrum peptide antigen of SARS-COV-2, a specific neutralizing antibody and use thereof. A broad-spectrum peptide antigen of SARS-COV-2, with an amino acid sequence comprising SEQ ID NO: 1, reacts with human SARS-COV-2 positive serum, and can specifically bind to a novel coronavirus antibody. Based on the peptide sequence of the present disclosure, a fusion protein with broad-spectrum triple tandem peptides of SARS-COV-2 is prepared using PCR, prokaryotic expression, and protein purification technology which simulates the trimeric mode of SARS-COV-2 S protein in its natural state. The fusion protein is used as an antigen to immunize mice, and can produce a specific anti-SARS-CoV-2 neutralizing antibody. The neutralizing antibody may be promising in anti-infective treatment, vaccine development and detection kit development for SARS-COV-2.